<?xml version="1.0" encoding="UTF-8"?>
<ref id="B73-biomedicines-08-00060">
 <label>73.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Galanis</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Markovic</surname>
    <given-names>S.N.</given-names>
   </name>
   <name>
    <surname>Suman</surname>
    <given-names>V.J.</given-names>
   </name>
   <name>
    <surname>Nuovo</surname>
    <given-names>G.J.</given-names>
   </name>
   <name>
    <surname>Vile</surname>
    <given-names>R.G.</given-names>
   </name>
   <name>
    <surname>Kottke</surname>
    <given-names>T.J.</given-names>
   </name>
   <name>
    <surname>Nevala</surname>
    <given-names>W.K.</given-names>
   </name>
   <name>
    <surname>Thompson</surname>
    <given-names>M.A.</given-names>
   </name>
   <name>
    <surname>Lewis</surname>
    <given-names>J.E.</given-names>
   </name>
   <name>
    <surname>Rumilla</surname>
    <given-names>K.M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase II trial of intravenous administration of Reolysin
   <sup>Â®</sup> (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma
  </article-title>
  <source>Mol. Ther.</source>
  <year>2012</year>
  <volume>20</volume>
  <fpage>1998</fpage>
  <pub-id pub-id-type="doi">10.1038/mt.2012.146</pub-id>
  <pub-id pub-id-type="pmid">22871663</pub-id>
 </element-citation>
</ref>
